Needham & Company LLC assumed coverage on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $42.00 price objective on the stock.
Needham & Company LLC assumed coverage on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $42.00 price objective on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.